Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. The Company’s multi antigen recognizing (MAR)-T cell technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, which are tumor targets, and kill tumor cells expressing those targets. These T cells are designed to recognize multiple tumor targets to produce broad-spectrum anti-tumor activity. It is developing two product candidates, including an Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601) and an Off-the-Shelf (OTS) product in various indications (MT-401-OTS). It has developed MT-601 to recognize multiple target antigens expressed by the tumor, thereby limiting tumor adaptation by negative antigen selection or downregulation.
Ticker SymbolMRKR
Company nameMarker Therapeutics Inc
IPO dateNov 08, 2016
Founded at2018
CEODr. Juan F. Vera, M.D.
Number of employees5
Security typeOrdinary Share
Fiscal year-endNov 08
Address2450 Holcombe Blvd
CityHOUSTON
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code77021
Phone17134006400
Websitehttps://markertherapeutics.com/
Ticker SymbolMRKR
IPO dateNov 08, 2016
Founded at2018
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data